Clinical trial NCT02529930: An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)
Official title: An Exploratory Safety and Immunogenicity Study of Human Papillomavirus (HPV16+) Immunotherapy VB10.16 in Women With High Grade Cervical Intraepithelial Neoplasia (HSIL; CIN 2/3)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: High Grade Cervical Intraepithelial Neoplasia
Keywords: HSIL
CIN 2/3
Therapeutic DNA vaccine
Human Papillomavirus
Immunotherapy
Lead sponsor: Nykode Therapeutics ASA
Sponsor class: INDUSTRY
Collaborators: name: Theradex
name: Vaccibody AS
First posted: 2015-08-20
Enrollment: 34
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is an exploratory, open, prospective multi-centre study of VB10.16 immunotherapy in patients with high grade HPV16+ Cervical Intraepithelial Neoplasia (HSIL; CIN2/3). This study will recruit approximately 27-40 female patients with high grade cervical intraepithelial neoplasia (HSIL, CIN 2/3) at multiple sites in Europe.

Detailed description: The study will be divided into two phases, a dosing and expansion phase.

During the dosing phase the safety, tolerability and immunogenicity of 2 different vaccination schedules of 3 mg VB10.16 immunotherapy will be established in a minimum of 12 patients with histology confirmed CIN 2.

During the expansion phase the safety, tolerability and immunogenicity of the selected vaccination schedule will be evaluated in approximately 15 to 20 patients with histology confirmed HPV16+ CIN 2/3.

Eligibility criteria: Inclusion Criteria (abbreviated):

1. Women ≥18 years
2. Women with ectocervical HPV16+ associated High Grade Cervical Intraepithelial Neoplasia (HSIL) as verified by local pathology:

   (Dosing Phase: Women with histologically confirmed HPV16+ associated CIN 2; Expansion Phase: Women with histologically confirmed HPV16+ associated CIN 2/3)
3. Satisfactory colposcopic examination.

Exclusion Criteria (abbreviated):

1. More than 2 cervical quadrants of CIN 3 as visualised by colposcopy.
2. Atypical glandular cells (AGC) or adenocarcinoma in situ (AIS) on cytology, malignant cells on cytology or histology or other suspicion of either micro-invasive or invasive disease.
3. Current severe pelvic inflammatory disease, severe cervicitis, or other severe gynaecological infection as per colposcopy and clinical examination.
4. Positive serological test for hepatitis C virus or hepatitis B virus surface antigen (HBsAg) or human immunodeficiency virus (HIV).
5. Administration of any blood product within 3 months of enrolment.
6. Concomitant or prior malignant disease.
7. Clinically significant autoimmune disease.
8. Known allergy to Kanamycin or other aminoglycosides
9. Known immunodeficiency and or immunosuppression.
10. History of toxic shock syndrome.
11. Evidence or history of clinically significant cardiac disease
12. Active infection requiring parenteral antibiotics.
13. Tattoos, scars, or active lesions/rashes within 2 cm of the site of vaccination or any implantable leads.
14. Immunosuppression
15. Major surgery within 3 months of trial entry.
16. Current or recent (within 30 days of first study treatment) participation in a clinical trial.
17. Previous vaccination (either therapeutic and/or prophylactic) against HPV.
18. Administration of any live vaccine within 90 days of trial entry.
19. Concomitant anticancer therapies.
20. Inadequate bone marrow function
21. Inadequate liver function
22. Clinical significant electrolyte abnormalities
23. Women of childbearing age not willing to use an effective form of contraception
24. Pregnancy or intention to become pregnant
25. Nursing women
26. Evidence of any other medical condition that may interfere with study participation, patient compliance or place the patient at high risk from treatment-related complications

Primary outcomes:
measure: Safety/tolerability
timeFrame: 6 months (extended follow up for additional 6 months)
Secondary outcomes:
measure: Immunogenicity
timeFrame: 6 months
measure: Preliminary assessment of efficacy
timeFrame: 6 months (extended follow up for additional 6 months)
Other outcomes:
Locations:
city: Hamburg
country: Germany
facility: Universitätsklinikum Hamburg-Eppendorf
state: Lower Saxony
city: Hannover
country: Germany
facility: Medical School Hanover
state: Lower Saxony
city: Wolfsburg
country: Germany
facility: Klinikum Wolfsburg
state: Lower Saxony
city: Hannover
country: Germany
facility: IZD Institut für Zytologie und Dysplasie
state: Niedersachsen
Study officials:
affiliation: Vaccibody AS
name: Irene Skjørestad, MSc
role: STUDY_DIRECTOR
References: